🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

545 results for “B.” Clear

  1. VSJ-110

    Vanda Pharmaceuticals Netherlands B.V.

    Allergic Conjunctivitis

    phase 2 small molecule completed

    1 trial

  2. VSJ-110

    Vanda Pharmaceuticals Netherlands B.V.

    Dry Eye

    phase 2 small molecule active

    2 trials

  3. Volixibat

    Mirum Pharmaceuticals International B.V.

    Primary Biliary Cholangitis

    phase 2 small molecule active

    1 trial

  4. Volixibat

    Mirum Pharmaceuticals International B.V.

    Intrahepatic Cholestasis of Pregnancy

    phase 2 small molecule terminated

    1 trial

  5. Volixibat

    Mirum Pharmaceuticals International B.V.

    Primary Sclerosing Cholangitis

    phase 2 small molecule active

    1 trial

  6. Zilebesiran

    Alnylam Netherlands B.V.

    High Cardiovascular Risk

    phase 2 small molecule completed

    1 trial

  7. Zilebesiran

    Alnylam Netherlands B.V.

    Mild to Moderate Hypertension

    phase 2 small molecule completed

    1 trial

  8. Zydena (Udenafil)

    Samsung Bioepis NL B.V.

    Vascular Dementia

    phase 2 small molecule active

    1 trial

  9. avelumab

    Samsung Bioepis NL B.V.

    Lymphoma, Extranodal NK-T-Cell

    phase 2 small molecule active

    1 trial

  10. cemdisiran

    Alnylam Netherlands B.V.

    Atypical Hemolytic Uremic Syndrome

    phase 2 small molecule terminated

    2 trials

  11. ifezuntirgene inilparvovec, ifezuntirgene inilparvovec

    uniQure biopharma B.V.

    Huntington’s Disease

    phase 2 small molecule active

    1 trial

  12. iloperidone

    Vanda Pharmaceuticals Netherlands B.V.

    Hypertension

    phase 2 small molecule active

    1 trial

  13. ivosidenib and nivolumab

    Agios Netherlands B.V.

    Advanced Solid Tumor

    phase 2 small molecule completed

    1 trial

  14. oritavancin

    Targanta Netherlands B.V.

    Staphylococcal Skin Infections

    phase 2 small molecule completed

    1 trial

  15. phosphate-buffered saline for SC administration

    Alnylam Netherlands B.V.

    Hereditary Hemorrhagic Telangiectasia (HHT)

    phase 2 small molecule active

    1 trial

  16. venglustat GZ402671 - SAR402671, IMIGLUCERASE, venglustat GZ402671 - SAR402671

    Genzyme Europe B.V.

    Gaucher disease type 3, Gaucher disease type 1

    phase 2 small molecule active

    1 trial

  17. vistusertib (AZD2014)

    Samsung Bioepis NL B.V.

    Small Cell Lung Cancer

    phase 2 small molecule terminated

    1 trial

  18. A First-in-Human Study to Evaluate the Safety and Tolerability of ALN-APP in Patients with EOAD

    Alnylam Netherlands B.V.

    Early-onset Alzheimer's disease (EOAD)

    phase 1 other active

    1 trial

  19. A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an anti-PD-1 Monoclonal Antibody, in Patients with Advanced Solid Tumors

    TESARO Bio Netherlands B.V.

    Patients with Advanced Solid Tumors

    phase 1 other active

    1 trial

  20. A Phase 1 Study of HMPL-306 in Advanced Hematological Malignancies with Isocitrate Dehydrogenase (IDH) Mutations

    Hutchmed Europe B.V.

    - Acute myeloid leukemia - Myelodysplastic syndrome/ Myeloproliferative neoplasm - Angio-immunoblastic T-cell lymphoma - Other mIDH-positive hematological malignancies (other than tumor types mentioned above)

    phase 1 other active

    1 trial

  21. A Phase 1 Study of HMPL-306 in Locally Advanced Solid Tumors with IDH mutations

    Hutchmed Europe B.V.

    - Locally advanced or metastatic solid tumors - Cholangiocarcinoma - Skeletal chondrosarcoma - Low-grade glioma - Any other solid tumor harboring an IDH mutation

    phase 1 other active

    1 trial

  22. A Phase 1 Study of TAS0612 in Patients with Locally Advanced or Metastatic Solid Tumors

    Taiho Pharma Netherlands B.V.

    Locally Advanced or Metastatic Solid Tumors

    phase 1 other active

    1 trial

  23. A Phase 1, First-in-Human Study of MEN2312, a KAT6 inhibitor, as Monotherapy and in Combination in Participants with Advanced Breast Cancer

    Stemline Therapeutics B.V.

    Advanced ER+/HER2- Breast Cancer

    phase 1 other active

    1 trial

  24. A Phase 1, Randomized, Placebo-controlled Study with a Double-blind Period with Open-label Extension Period to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intrathecally Administered ALN-5288 in Adult Patients with Alzheimer’s Disease

    Alnylam Netherlands B.V.

    Alzheimer’s Disease

    phase 1 other active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources